Lansoprazol is an anti-ulcer drug that is a specific inhibitor of H + -K + -ATP-ase.
Release form and composition
Lansoprazole is available in the form of capsules of green color, the contents of which are microgranules of white or almost white color (7 pieces in blisters, in a cardboard bundle 2 packs).
The active ingredient of the drug is lansoprazole, in 1 capsule - 30 mg.
Indications for use
- Stressful ulcers;
- Peptic ulcer and duodenal ulcer;
- Zollinger-Ellison Syndrome;
- Erosive and ulcerative esophagitis;
- Reflux esophagitis;
- Erosive and ulcerative lesions of the stomach and duodenum associated with Helicobacter pylori;
- Erosive and ulcerative lesions of the stomach and duodenum due to nonsteroidal anti-inflammatory drugs (NSAIDs).
- I trimester of pregnancy;
- Breastfeeding period;
- Hypersensitivity to the drug.
During the treatment period, elderly people, patients with renal and hepatic insufficiency should be under special observation.
It is not recommended to prescribe Lansoprazole to children and adolescents under 18 years, because Clinical data confirming the efficacy and safety of the drug in this age group of patients is not enough.
Dosing and Administration
The drug is intended for oral administration.
- The exacerbation of duodenal ulcer - 30 mg / day, in cases of increased resistance, the dose is increased to 60 mg, the duration of treatment is 2-4 weeks;
- Erosive and ulcerative esophagitis and exacerbation of gastric ulcer - 30-60 mg / day for 4-8 weeks;
- Erosive and ulcerative lesions of the gastrointestinal tract (GIT) caused by taking NSAIDs - 30 mg / day for 4-8 weeks;
- Antirecurrent therapy of reflux esophagitis - 30 mg / day, a long course of treatment - up to 6 months;
- Eradication of Helicobacter pylori - 30 mg 2 times a day in combination with antibacterial drugs, the duration of treatment is 10-14 days;
- Anti-relapse therapy of gastric ulcer and duodenal ulcer - 30 mg per day.
In Zollinger-Ellison syndrome, the doctor selects the dose individually, the goal of therapy is to achieve basal secretion to less than 10 mmol / h.
- Central nervous system: headache; rarely - dizziness, anxiety, drowsiness, malaise, depression;
- The digestive system: abdominal pain, decrease or increase in appetite, nausea; rarely diarrhea / constipation; in rare cases, ulcerative colitis, increased transaminase activity of the liver, candidiasis of the gastrointestinal tract, hyperbilirubinemia;
- Hematopoietic system: rarely - thrombocytopenia, accompanied by hemorrhagic manifestations; in individual cases - anemia;
- Respiratory system: rarely - pharyngitis, cough, infections of the upper respiratory tract, rhinitis, flu-like syndrome;
- Allergic reactions: skin rash; in rare cases, erythema multiforme and photosensitization;
- Other: in rare cases - alopecia and myalgia.
Before the appointment of lansoprazole and after the end of the course of treatment, the presence of a malignant neoplasm should be excluded, since the drug can mask the symptoms of such diseases and delay the timely diagnosis.
Sucralfate reduces the bioavailability of lansoprazole by 30%; therefore, an interval of 30-40 minutes should be observed between taking these drugs.
Lansoprazol reduces theophylline clearance by 10%, accelerates pH-dependent absorption of agents belonging to base groups, and slows down the absorption of preparations belonging to weak acid groups.
Antacids should be taken 1 hour before or 2-3 hours after taking lansoprazole, because they slow down and reduce its absorption.
Lansoprazole slows down the excretion of drugs metabolized in the liver by microsomal oxidation, such as phenytoin, diazepam and indirect anticoagulants.
Terms and conditions of storage
Store at a temperature not exceeding 25 ° C in a dry, dark place.
Shelf life - 2 years.